Selank (TBKP; Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a structural analog of the endogenous immunomodulatory tetrapeptide tuftsin, extended with a Pro-Gly-Pro sequence to enhance metabolic stability. Selank has been the subject of preclinical and early translational investigations examining its interactions with inhibitory neurotransmitter systems, particularly the GABAergic pathway.
This article provides an overview of the preclinical mechanistic research surrounding Selank, with focus on two major proposed pathways: allosteric modulation of GABA-A receptors and inhibition of enkephalin-degrading enzymes. All information is drawn from peer-reviewed published studies and is intended strictly as a summary of preclinical science.
Molecular Structure and Research Context
Selank’s amino acid sequence – Thr-Lys-Pro-Arg-Pro-Gly-Pro – gives it several properties of interest for neuropharmacology research. The Pro-Gly-Pro extension at the C-terminus, shared with another well-studied peptide Semax, is associated with resistance to protease-mediated degradation in biological media. Researchers have proposed that this stability profile allows Selank to interact with receptor systems and enzyme substrates for longer durations than unmodified neuropeptides.
Selank has been classified pharmacologically as a peptide anxiolytic in preclinical models, exhibiting a behavioral profile in rodent assays that has been compared to classical benzodiazepines. Unlike benzodiazepines, however, Selank is not a direct GABA-A ligand in the traditional sense – its mechanistic interaction with the GABAergic system appears to be indirect and genomic in nature.
Mechanism 1: GABA-A Receptor Gene Expression Modulation
A 2016 study published in Frontiers in Pharmacology by Shadrina et al. (PMID: 26924987; DOI: 10.3389/fphar.2016.00031) examined the effect of Selank administration on mRNA expression of 84 genes related to GABAergic neurotransmission in rat frontal cortex. The investigators found statistically significant changes in the expression of multiple GABA-A receptor subunit genes at 1 and 3 hours post-administration, as well as in genes encoding GABA transporters (notably Slc6a11) and associated ion channels.
The research team noted that the pattern of gene expression changes observed after Selank administration overlapped with certain transcriptional signatures seen following GABA administration alone, supporting the hypothesis that Selank’s behavioral effects may involve modulation of the GABAergic system. The authors concluded that “one of its possible molecular mechanisms is associated with allosteric modulation of the operation of the GABAergic system,” while noting that serotonergic and dopaminergic systems may also be involved.
A follow-up study (Filatova et al., 2017; DOI: 10.3389/fphar.2017.00089; PMID: 28293190), also published in Frontiers in Pharmacology, extended this line of inquiry to human neuroblastoma cells (IMR-32). Incubation of IMR-32 cells with Selank produced significant changes in the expression of GABA transporter genes (SLC6A11) and neuropeptide receptor genes, providing an in vitro cellular model that complements the in vivo rodent data.
Mechanism 2: Enkephalinase Inhibition and Endogenous Opioid Peptide Preservation
The second major mechanistic pathway investigated in Selank research involves the inhibition of enzymes responsible for degrading endogenous enkephalins in serum. Enkephalins are endogenous opioid neuropeptides with known roles in modulating anxious states in rodent models.
Kost et al. (2001; PMID: 11550013; DOI: 10.1023/a:1011373002885) demonstrated in vitro that both Selank and Semax inhibit enkephalin-degrading enzymes (specifically neprilysin/neutral endopeptidase activity) isolated from human serum. By slowing the proteolytic degradation of leu-enkephalin and met-enkephalin, Selank may extend the half-lives of these endogenous peptides in biological preparations – a mechanism researchers have proposed as contributing to the peptide’s observed behavioral effects in preclinical assays.
Key Preclinical Findings: UCMS Stress Model
Kasian et al. (2017; PMID: 28280289; DOI: 10.1155/2017/5091027), publishing in Behavioural Neurology, investigated Selank’s interaction with diazepam in a rat unpredictable chronic mild stress (UCMS) paradigm. The investigators found that Selank monotherapy reduced experimentally elevated anxiety-like behavior scores in UCMS-exposed rats and that co-administration of Selank with diazepam produced effects greater than either compound individually in this model. The authors noted that these findings are consistent with the hypothesis of a shared or complementary interaction with the GABA-A receptor system.
This additive interaction observed in the UCMS model is of interest to researchers studying the pharmacology of GABAergic peptides, as it suggests that Selank’s interaction with the GABAergic system may be mechanistically distinct from classical benzodiazepine binding – potentially acting through allosteric sites or via the transcriptional/translational regulation described in the gene expression studies above.
Frequently Asked Questions
What is Selank’s proposed mechanism of action in preclinical research?
Preclinical research has proposed two primary mechanisms: (1) modulation of GABA-A receptor gene expression – specifically changes in mRNA levels of GABA receptor subunits and GABA transporter genes in rodent frontal cortex; and (2) inhibition of enkephalin-degrading serum enzymes such as neprilysin, which may preserve endogenous enkephalin activity in biological preparations. Both mechanisms have been characterized in peer-reviewed studies using in vivo rodent and in vitro cell line models.
How does Selank differ from classical benzodiazepines in preclinical models?
Classical benzodiazepines act as direct positive allosteric modulators at the benzodiazepine binding site of the GABA-A receptor. Selank, by contrast, has not been shown to directly bind this site. Instead, preclinical evidence indicates that Selank modulates GABAergic neurotransmission at the level of gene expression – altering the mRNA levels of receptor subunits and transporters – rather than through direct receptor binding. This distinction has been the subject of ongoing investigation in the published literature.
What is the significance of enkephalinase inhibition in Selank research?
Enkephalins (leu-enkephalin and met-enkephalin) are endogenous opioid neuropeptides that are rapidly degraded by serum enzymes including neprilysin. In vitro research has shown that Selank inhibits these degradative enzymes in human serum preparations, extending the half-life of enkephalins in the test system. Because enkephalins interact with mu and delta opioid receptors that modulate inhibitory tone in the central nervous system, researchers have proposed this enzyme inhibition as a contributing factor to Selank’s observed preclinical effects. This remains an active area of investigation.
What animal models have been used to study Selank?
The primary preclinical models used to investigate Selank include the elevated plus maze, open field test, and unpredictable chronic mild stress (UCMS) paradigms in rats and mice. Gene expression studies have been conducted in rat frontal cortex tissue following acute Selank administration, and complementary in vitro studies have used human IMR-32 neuroblastoma cells. Primate work at the Institute of Higher Nervous Activity has examined mnemonic effects in monkey models.
Is Selank available for human use?
Selank sold by Core Research Peptides is a research compound supplied strictly for in vitro and laboratory research purposes. It is not approved for human consumption or therapeutic use in the United States. Researchers interested in this peptide should review the current peer-reviewed literature via PubMed and consult institutional biosafety protocols before beginning any experimental work.
This content is for informational and educational purposes only. All products sold by Core Research Peptides are for research use only and not for human consumption.
In stock now
Selank 10mg, in stock in the United States
Core Research Peptides stocks Selank 10mg at $48 a vial with published bundle pricing at two, three and five units. Orders placed before 4PM ET dispatch the same day, seven days a week.
Read the Selank buying guideView Selank 10mgFree research guide for this compound at coreresearchpeptides.com/guides.
